In summary, the results of this experiment suggest that febuxostat can effectively reduce the levels of urine NGAL/creatinine and urine KIM-1/creatinine, which have a protective effect on early renal tubular injury caused by hyperuricemia and provide a basis for the early treatment of asymptomatic hyperuricemia. Here, LCN2 is linked to hyperuricemia.